Surfing the NASH Tsunami Podcast Artwork Image

Surfing the NASH Tsunami

HEP Dynamics LLC

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Stephen Harrison, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green as they discuss the issues affecting the evolving NASH market from their own unique perspectives on the Surfing the NASH Tsunami podcast. #NASH #NAFLD #FattyLiver

Recent Episodes

S2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH CongressApril 18, 2021 Episode artwork S2-E19.2 - Patient-Centric Themes At The 4th Global NASH CongressApril 17, 2021 Episode artwork S2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH CongressApril 17, 2021 Episode artwork S2-E19 - Previewing the 4th Global NASH congressApril 14, 2021 Episode artwork S2 E18.3 -- Stephen Harrison and Alina Allen discuss what her work portends for future trials.April 11, 2021 Episode artwork S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?April 10, 2021 Episode artwork S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?April 10, 2021 Episode artwork S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patientsApril 07, 2021 Episode artwork S2-E17.3 -- The value of ultrasound and the goals of patient screeninApril 04, 2021 Episode artwork S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levelsApril 03, 2021 Episode artwork S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?April 03, 2021 Episode artwork S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithmsMarch 31, 2021 Episode artwork S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to MarketMarch 28, 2021 Episode artwork S2-E16.2 - Future Directions for NASH Cost-Effectiveness ResearchMarch 27, 2021 Episode artwork S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has EvolvedMarch 27, 2021 Episode artwork S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and TreatmentMarch 24, 2021 Episode artwork S2-E15 — Wrapping Up NASH-TAG 2021March 17, 2021 Episode artwork S2-E14 - NASH-TAG Session 4 Summary: Basic Science and Promising Drugs on the HorizonMarch 14, 2021 Episode artwork S2-E13 - NASH-TAG Session 3 Summary: Trial Designs of the Future and the Future of Diabetes Drugs in NASHMarch 14, 2021 Episode artwork S2-E12 - NASH-TAG Session 2 Summary: Innovative Trial Design and Robust Histologic AnalysesMarch 13, 2021 Episode artwork S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail March 12, 2021 Episode artwork S2 E10 — Before NASH-TAG, Conversations With Co-DirectorsMarch 10, 2021 Episode artwork S2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public HealthMarch 07, 2021 Episode artwork S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver diseaseMarch 07, 2021 Episode artwork S2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity mattersMarch 07, 2021 Episode artwork